TIKOMED ILB - Pleiotropic Mechanisms Drugs
ILB’s mechanism of action may either reduce the triggers that lead to cell death or prevent further pathology even if triggers are present. By addressing the underlying processes of disease, ILB could significantly improve outcomes for people suffering from otherwise untreatable progressive and disabling conditions.
Details
- Broad applicability in acute and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and stroke plus traumatic brain injury and glaucoma.
- Addresses the underlying pathology of the diseases, enabling self-repair instead of just treating the symptoms.
- Subcutaneous dosing simplifies administration for the patient and makes it suitable for longer term treatment.
Features
- Activates MMPs and blocks pro-fibrotic TGF-β.
- Increases glutamate uptake.
- Pro-angiogenic and attenuates angiopathies.
- Normalizes mitochondrial function.
- Attenuates microglial activation.
- Blocks β-amyloid oligomerisation and plaque formation.
- Stabilizes neurofilaments and enhances growth factor transport.
Development phases
ILB has a solid set of non-clinical and clinical data covering a broad range of indications and further studies with our development partners are planned. These will be used as a basis for CRO-monitored Phase II clinical trials planned for ALS, glaucoma, stroke, and traumatic brain injury.
Customer reviews
No reviews were found for TIKOMED ILB - Pleiotropic Mechanisms Drugs. Be the first to review!